GlassScriptPhysician profile
Reena D Jain
NPI 1538171723
$4,020.70
in general payments reported to CMS, 2019-2025
26 companies · $1,263 in 2025
The $1,263 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $607 · 2022: $452 · 2023: $664 · 2024: $1,034 · 2025: $1,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871 · Education: $90.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.02 |
| Education | $90.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $565.85 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $482.45 | 2021-2025 | Otezla, Otezla |
| Abbvie INC. | $479.14 | 2022-2025 | |
| Genzyme Corporation | $266.81 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $251.88 | 2023-2025 | Zoryve |
| Pfizer INC. | $245.88 | 2021-2025 | |
| Dermavant Sciences, INC. | $223.51 | 2023-2024 | Vtama |
| Lilly USA, LLC | $198.40 | 2021-2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $179.92 | 2021-2025 | Odomzo, Blu-U, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $149.33 | 2023-2025 | Sotyktu |
| Ucb, INC. | $135.90 | 2024-2025 | Bimzelx |
| Incyte Corporation | $113.25 | 2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $111.53 | 2021 | |
| Organon LLC | $97.92 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $90.26 | 2024-2025 | Libtayo, Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $84.45 | 2021-2025 | Jublia |
| Mayne Pharma Commercial LLC | $61.44 | 2022-2025 | |
| Revance Therapeutics, INC. | $59.06 | 2024 | Daxxify |
| Galderma Laboratories, L.P. | $48.78 | 2021-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $36.12 | 2021-2025 | |
| Botanix Sb INC | $35.88 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $25.86 | 2023 | Poteligeo |
| Genentech USA, INC. | $23.45 | 2021 | |
| Almirall LLC | $21.04 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $16.49 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.10 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.